TCIM
IONS icon

TIAA CREF Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

TIAA CREF Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$14.5M Buy
178,392
+65,134
+58% +$4.2M 0.01% 856
2018
Q4 		$6.12M Sell
113,258
-184,145
-62% -$9.39M ﹤0.01% 1250
2018
Q3 		$15.3M Sell
297,403
-6,204
-2% -$291K 0.01% 871
2018
Q2 		$12.7M Sell
303,607
-7,720
-2% -$342K 0.01% 999
2018
Q1 		$13.7M Sell
311,327
-9,851
-3% -$500K 0.01% 939
2017
Q4 		$16.2M Sell
321,178
-17,027
-5% -$934K 0.01% 884
2017
Q3 		$17.1M Sell
338,205
-26,412
-7% -$1.38M 0.01% 835
2017
Q2 		$18.5M Buy
364,617
+5,168
+1% +$241K 0.01% 797
2017
Q1 		$14.4M Sell
359,449
-8,251
-2% -$371K 0.01% 899
2016
Q4 		$17.6M Sell
367,700
-15,460
-4% -$612K 0.01% 808
2016
Q3 		$14K Buy
383,160
+20,521
+6% +$642K 0.01% 931
2016
Q2 		$8.45M Sell
362,639
-1,357
-0.4% -$43.8K 0.01% 1160
2016
Q1 		$14.7M Sell
363,996
-17,435
-5% -$708K 0.01% 865
2015
Q4 		$23.6M Sell
381,431
-446
-0.1% -$24.1K 0.02% 705
2015
Q3 		$15.4M Sell
381,877
-15,146
-4% -$784K 0.01% 837
2015
Q2 		$22.8M Sell
397,023
-153,608
-28% -$9.77M 0.02% 739
2015
Q1 		$35.1M Sell
550,631
-743
-0.1% -$50.4K 0.02% 589
2014
Q4 		$34M Sell
551,374
-23,358
-4% -$1.15M 0.02% 581
2014
Q3 		$22.3M Sell
574,732
-13,156
-2% -$466K 0.02% 732
2014
Q2 		$20.3M Buy
587,888
+24,688
+4% +$777K 0.01% 781
2014
Q1 		$24.3M Sell
563,200
-9,001
-2% -$436K 0.02% 714
2013
Q4 		$22.8M Buy
572,201
+33,432
+6% +$1.19M 0.02% 737
2013
Q3 		$20.2M Buy
538,769
+16,055
+3% +$480K 0.02% 745
2013
Q2 		$14M Buy
+522,714
New +$11.1M 0.01% 863

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's IONS Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Ionis Pharmaceuticals (IONS) stake by 58% in Q1 2019, buying an estimated $4.2M and bringing the position to 178,392 shares worth $14.5M. The position accounts for 0.01% of the portfolio, ranked #856.

TIAA CREF Investment Management first reported a position in IONS in Q2 2013 and has held it in 24 quarters since. The position peaked at $35.1M in Q1 2015. 392 funds tracked by Wall St. Rank hold IONS as of Q1 2019.

  • TIAA CREF Investment Management held 178,392 shares of Ionis Pharmaceuticals worth $14.5M as of Q1 2019.
  • TIAA CREF Investment Management bought 65,134 Ionis Pharmaceuticals shares in Q1 2019, an estimated $4.2M.
  • Ionis Pharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #856 holding.
  • TIAA CREF Investment Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Ionis Pharmaceuticals position peaked at $35.1M in Q1 2015.
  • 392 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.